Market Overview

Morgan Stanley Upgrades Anthem, Sees Opportunity In Pharmacy Benefit Manager Shakeup

Share:
Morgan Stanley Upgrades Anthem, Sees Opportunity In Pharmacy Benefit Manager Shakeup

Mergers and regulated pricing reform have shaken the pharmacy benefits management space — and the chaos may play out in Anthem Inc (NYSE: ANTM)’s favor.

The Analyst

Morgan Stanley analyst Zack Sopcak upgraded Anthem from Equal-weight to Overweight and increased the price target from $273 to $368.

The Thesis

By Sopcak’s estimates, Anthem should seize underappreciated market share and post accelerated profit growth in a post-rebate environment that champions transparency. (See the analyst's track record here.) 

“Rapid evolution of the PBM market and model greatly advantages an integrated managed care (MCO)/PBM solution, in our view, just as Anthem is bringing its PBM in-house,” Sopcak said. Anthem’s withdrawal from the Express Scripts Holding Co (NASDAQ: ESRX) service is seen to set the stage for incremental scale.

Considering UnitedHealth Group Inc (NYSE: UNH)’s precedent in integrating its PBM, as well as Anthem leadership’s involvement in UnitedHealth’s execution, Sopcak expects Anthem to record $1.1 billion in PBM-driven pretax profit in 2021. With relatively low risk, the transition is seen to yield a fresh and profitable opportunity.

“Tighter integration of pharmacy with medical benefits should both enhance Anthem's margins and opportunities to compete for new business in Medicare and Medicaid,” the analyst said. “In addition, we model heightened capital deployment, which could consist of tuck-in M&A akin to recent deals or share repurchases,as the PBM accelerates free cash generated and access to unregulated capital starting in 2020.”

Morgan Stanley raised its price target to account for Anthem’s PBM in-sourcing, underappreciated PBM growth and accelerated core growth.

Price Action

Anthem shares were trading up 1.3 percent to $267.13 off the open Wednesday. 

Related Links:

Castlight Health Has $10B Potential Market, William Blair Says In Bullish Initiation

Why Bernstein is Skeptical Of Cigna's Move to Buy Express Scripts

Latest Ratings for ANTM

DateFirmActionFromTo
Sep 2019MaintainsOverweight
Sep 2019Initiates Coverage OnBuy
Jul 2019MaintainsOverweight

View More Analyst Ratings for ANTM
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Zack SopcakAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (ESRX + ANTM)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NVDACascendMaintains220.0
ADBECleveland ResearchInitiates Coverage On283.0
IMOCiBCUpgrades
RETAJefferiesMaintains254.0
SNAPAreteUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

10 Biggest Price Target Changes For Wednesday

Benzinga Pro's 6 Stocks To Watch Today